Press Releases

Press Releases

Samsung Biologics Plans IPO on KOSPI

Samsung Biologics Plans IPO on KOSPI

 

- To secure capital for investments as it aims to become a  top-tier biopharmaceutical manufacturing company

- Will continue to strengthen its presence in the rapidly growing global biopharmaceutical market 

 

 

[INCHEON, KOREA] April 28, 2016 - Samsung Biologics on Thursday announced plans for an initial public offering on the KOSPI (Korea Composite Stock Price Index) this year, following a resolution at the Board of Directors.

 

Through the IPO, Samsung Biologics will be able to secure funds for investments and research into technology innovation as it aims to become a global top-tier biopharmaceutical manufacturing company.

 

Samsung Biologics will select lead managers for the IPO next month to decide on the exact timing of the listing and the volume of shares to be offered.

 

"We are pleased with our sustainable expansion through continuous investments and innovation,” said Dr. TH Kim, CEO of Samsung Biologics. "We will continue to strengthen our competitiveness in order to deliver long-term growth and create meaningful value to our customers and shareholders.”

 

The global biopharmaceutical industry is expected to expand to almost $278 billion by 2020, with an annual growth rate of more than 8% on average, according to a World Preview 2015 report by research firm Evaluate Pharma, amid an aging population and the development of medical technology.

 

Samsung Biologics aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency.

 

Samsung Biologics is investing a total 850 billion won in its third plant with a capacity of 180,000 liters, which is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation.

 

Once in operation in 2018, Samsung Biologics is expected to become the world’s largest contract manufacturing organization (CMO) for biologics, with a total production capacity of 360,000 liters.

 

 

These materials are not an offer for sale of the securities of Samsung Biologics Co., Ltd. in the United States. The securities may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. Samsung Biologics Co., Ltd. does not intend to register any offering in the United States or to conduct a public offering of securities in the United States. 

 

Not for distribution in the United States.

 

Samsung Biologics Plans IPO on KOSPI

 

- To secure capital for investments as it aims to become a  top-tier biopharmaceutical manufacturing company

- Will continue to strengthen its presence in the rapidly growing global biopharmaceutical market 

 

 

[INCHEON, KOREA] April 28, 2016 - Samsung Biologics on Thursday announced plans for an initial public offering on the KOSPI (Korea Composite Stock Price Index) this year, following a resolution at the Board of Directors.

 

Through the IPO, Samsung Biologics will be able to secure funds for investments and research into technology innovation as it aims to become a global top-tier biopharmaceutical manufacturing company.

 

Samsung Biologics will select lead managers for the IPO next month to decide on the exact timing of the listing and the volume of shares to be offered.

 

"We are pleased with our sustainable expansion through continuous investments and innovation,” said Dr. TH Kim, CEO of Samsung Biologics. "We will continue to strengthen our competitiveness in order to deliver long-term growth and create meaningful value to our customers and shareholders.”

 

The global biopharmaceutical industry is expected to expand to almost $278 billion by 2020, with an annual growth rate of more than 8% on average, according to a World Preview 2015 report by research firm Evaluate Pharma, amid an aging population and the development of medical technology.

 

Samsung Biologics aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency.

 

Samsung Biologics is investing a total 850 billion won in its third plant with a capacity of 180,000 liters, which is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation.

 

Once in operation in 2018, Samsung Biologics is expected to become the world’s largest contract manufacturing organization (CMO) for biologics, with a total production capacity of 360,000 liters.

 

 

These materials are not an offer for sale of the securities of Samsung Biologics Co., Ltd. in the United States. The securities may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. Samsung Biologics Co., Ltd. does not intend to register any offering in the United States or to conduct a public offering of securities in the United States. 

 

Not for distribution in the United States.

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION